Documentation, coding, charging, and billing for medications
Identifying risks and internal audit focus areas
Introduction

Medications administered to patients in both the inpatient and outpatient settings must be properly documented to support the coding and billing requirements for pharmaceutical drugs. The administration of drugs is documented by clinicians in the patient’s medication administration record, a component of the patient’s permanent medical record. Medical coders and billers abstract the quantity and type of drugs administered from the medical record, assign the appropriate codes, and create a claim to be submitted for reimbursement. Drugs must also be identified and reported using a unique number, called the National Drug Code (NDC), which serves as a universal product identifier for the drugs.

The pharmacy is responsible for determining compliance with ordering guidelines, which typically requires that a medication order contain the patient name; age and weight; date and time of the order; drug name; dose, frequency, name of prescriber; and where applicable, the exact strength/concentration, quantity/duration, and other specific instructions for use.

The pharmacy department is often an area of focus for financial, compliance, and operations focused internal and external audits given its high dollar spend and impact on patient care. The function is frequently the subject of surveys, site visits and audits by accreditation groups, Centers for Medicare & Medicaid Services (CMS), Office of Inspector General (OIG), Drug Enforcement Administration (DEA) or state licensing boards for pharmacy and medicine.
The pharmacy revenue cycle includes the following primary areas: pharmacy purchasing data, dispensing transactions, charge description master (CDM), pharmacy charges, and patient billing. Many organizations may lack the level of vigilance and proper maintenance of the pharmacy revenue cycle that will ensure this process performs effectively. Successful matching of each step of the process ensures that the pharmacy billing and transactions files provide the correct information to the hospital CDM and/or the hospital billing system, and that the correct billing data are submitted to payers on the UB04.
Some key risks

One of many risks facing the pharmacy department is the proper documentation and tracking of both used and unused medications. If a drug has been discontinued or was unused, the drug should be returned immediately to the pharmacy and credited to the patient account if charges were generated upon initial distribution. Drug distribution systems and processes should be periodically reviewed, and circumventing distribution controls or the stockpiling of unused drugs should not be allowed.

The pharmacy department must be responsible for the procurement, distribution, and control of all drugs used within the organization. The use of night cabinets, drug carts, and other methods discourages the need for non-pharmacy personnel to enter the pharmacy; however, access controls over these solutions must be evaluated to ensure that only those individuals who need access actually have access.

Another significant risk is missed pharmacy charges. In order to identify missing drugs, the pharmacy should reconcile the total drugs administered to the patient against the total drugs billed. Charge variances should be promptly investigated to determine the root cause of the discrepancy. Ongoing education should be conducted by the pharmacy and the billing departments to discuss reconciliation errors with staff, as well as identify the causes of their errors and methods to prevent them.

The pharmacy department must be responsible for the procurement, distribution, and control of all drugs used within the organization.
Some key questions to consider

To comply with coding, billing and documentation requirements, pharmacy management should proactively consider and address several key questions regarding their operations:

• How is the medication administered to patients documented? Does the documentation include key elements such as the quantity, administration date, administration intervals, start and stop times, and prescriber information?

• What is the process for charging patient accounts?
  a. Are patient accounts automatically billed when drugs are dispensed or upon administration?
  b. Do charges need to be manually entered into patient accounts based on the Medication Administration Record (MAR)?
  c. What types of adjustments can be made to the charges?
  d. If compounding is completed, how are compounded drugs documented and charged?

• How are unused medications returned or disposed/wasted, documented, and credited to the patient account and inventory?

• How is waste documented and billed in certain situations?

• How are variances identified between medications purchased and medications billed?

• Is the CDM reviewed on a periodic basis and can it be modified only by appropriate personnel?

• How is pharmaceutical pricing determined? Is pricing information accurate?

• How is the NDC to HCPCS billing unit conversion factor configured?

• What is the pricing methodology for specialty drugs?
Considerations when conducting an internal audit

The following are some example activities to consider when conducting an internal audit:

• Compare a sample of orders with patient charges and a sample of patient charges with orders, and determine root cause for any differences.

• Review the override report for drug distribution systems to determine if departments or users are circumventing controls. Assess whether management is performing an active, timely review of overrides. Confirm that discrepancies noted during the review are formally documented and investigated.

• Assess whether interfaces between pharmacy and billing systems are reviewed for errors and adjustments.

• Determine if there is an approved override listing to allow for emergency pharmaceutical usage. Assess whether management is performing a review of the emergency usage to confirm that the medication that has been overridden has been approved and accounted for.

• Determine if access to the drug distribution system is periodically reviewed.

• Review revenue and volume reports to confirm appropriateness and consistency of transactions.

• Conduct an analysis of the charge capture processes and assess how the charge description master generates the drug charge using the NDC database and converts it to the appropriate billing unit

• Assess denials and corrected claims for reasonableness of volumes. Evaluate the effectiveness of pre-billing edits.

• Review a sample of high priced drugs and assess coding accuracy.

• Determine how HCPCS J-codes for injectable drugs are periodically reviewed and updated.

• Determine how local coverage determinations (LCDs) and national coverage determinations (NCDs) are incorporated into the claims process.

Conducting a pharmacy revenue cycle internal audit is critical given the multi-disciplinary responsibilities spanning from pharmacists, pharmacy buyers, coding, billing, to patient financial services.

• Determine if a process exists to discard or return unused medications. Assess whether the pharmacy is reconciling unused medications and applying a credit to the patient account.

• Test to confirm that medications must first be approved by the pharmacy prior to distribution.

• Review a sample of medications administered to confirm that they are supported by a medication order. Assess whether the order is compliant with ordering guidelines.

• Determine if a review is performed to identify medication dispensed from the drug distribution system that has not been assigned to a patient. Assess whether a process is in place to charge the medication administered to a patient account for billing.

• Conducting a pharmacy revenue cycle internal audit is critical given the multi-disciplinary responsibilities spanning from pharmacists, pharmacy buyers, coding, billing, to patient financial services. These internal audits typically identify opportunities to improve revenues and reduce the potential for billing errors.
References

http://www.fda.gov/drugs/informationondrugs/ucm142438.htm


Contacts

AHIA

Mark Eddy, CPA
HCA Healthcare
Mark.Eddy@HCAHealthcare.com

Michael Fabrizius, CPA
Carolinas Healthcare System
michael.fabrizius@carolinashealthcare.org

Glen Mueller, CPA (Chair)
Scripps Health
Mueller.Glen@scrippshealth.org

Debi Weatherford, CPA
Piedmont Healthcare
debi.weatherford@piedmont.org

Mark Ruppert, CPA
Cedars-Sinai Health System
Mark.Ruppert@cshs.org

Deloitte

Kevin Wijayawickrama
Principal
Deloitte & Touche LLP
kevinw@deloitte.com

Neetu Khilnani
Senior Manager
Deloitte & Touche LLP
nkhilnani@deloitte.com

Karolyne Woo
Senior Manager
Deloitte & Touche LLP
kwoo@deloitte.com

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see www.deloitte.com/about for a detailed description of DTTL and its member firms. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Copyright © 2014 Deloitte Development LLC. All rights reserved.
Member of Deloitte Touche Tohmatsu Limited